Special Programs

Innovations and Partnerships with the U.S. Department of Defense

9:00 AM–12:00 PM Jun 19, 2017 (America - Los Angeles)

Room 6A, Upper Level


Because of its global presence, the U.S. Department of Defense has a continuing interest in providing medical countermeasures against select agents and emerging threats in creative and sustainable ways. Innovations in biotechnology can be used to protect against chemical and biological threats, and can also require new ways to mitigate the risk of unintentional consequences or intentional misuse of these technologies.

The session will feature multiple panel discussions on a variety of topics including a strategic overview with key leaders of the DoD's Chemical and Biological Defense Program, avenues for biotechnology companies to communicate and work with the DoD, highlighting DoD's inventive new business processes to increase efficiency, and exploring technical innovations that can provide game-changing capability for medical countermeasures development.

Keynote: Commitment to Partnerships
Speaker: Dr. Jason Roos (DJPEO)

Panel 1: Business Innovations
This panel will feature a discussion of the business innovations that the DoD has been exploring or has already implemented, such as Priority Review Vouchers (PRVs), Other Transaction Agreements (OTAs) and the streamlining of our DAU activities. The Advanced Development Manufacturing facility will also be discussed.
Moderator: Phyllis Arthur, BIO
Speaker 1: Dr. Julie Boylan (DTRA)
Speaker 2: Tim Belski (MCS-ADMC)
Speaker 3: Scott White (JPM-IS)
Speaker 4: Jeremiah Kelly (USAMRMC JAG)

Panel 2: Technical Innovations
This panel will feature a discussion of the technical capabilities DoD either needs to overcome or harness as an ability to maintain control in the arena. These priorities provide military protection and global health security. -Game-changers, such as BSCAV, DX capabilities and dormant technologies -Ways to use new technology for good and ability to defeat malicious use of novel technology
Moderator: Sara Terpening (Nanotherapeutics, Inc.)
Speaker 1: Dr. George Christopher (CMO)
Speaker 2: LTC Matthew Clark (CDP)
Speaker 3: Dr. Julie Boylan (DTRA)
Speaker 4: Jennifer Dabisch (MCS-DX)
Speaker 5: Dr. Brad Ringeisen (DARPA)

Session ID: 25790